Sézary syndrome represents a type of blood malignancy ... Laboratory test to assess a complete blood count is initially performed. Peripheral blood smear, immunophenotyping, T-cell receptor ...

The classical forms of CTCL are plaque-type mycosis fungoides (MF) and Sezary syndrome (SS). SS is a rare, leukemic variant of CTCL that typically presents with erythroderma, peripheral ...

The standardization of a sensitive ELISA for the quantification of SHP-1 protein in peripheral T and B lymphocytes ... T cells from patients with Sezary syndrome and in the Sezary T cell line ...

Peripheral neuropathy was the most common adverse event. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). 1–3 Patients with early stage ...

Sézary syndrome. KIR3DL2 is expressed in up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues. Lacutamab has been ...

Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues. Lacutamab is granted ...

in particular Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues. Cohort 1 ...

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS ... in combination with other anti-lymphoma agents in peripheral T-cell lymphomas (PTCL).